查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
IBD(潰瘍性大腸炎、克隆氏症)治療藥的全球市場:產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)
市場調查報告書
商品編碼
1121676

IBD(潰瘍性大腸炎、克隆氏症)治療藥的全球市場:產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)

IBD [Ulcerative Colitis & Crohn's Disease] Treatment Market (Drug Class: TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Corticosteroids, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 211 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球IBD(潰瘍性大腸炎、克隆氏症)治療藥市場相關調查分析，市場促進因素和阻礙因素，機會，COVID-19影響，各市場區隔的分析與預測，各地區分析，企業簡介等資訊。

目錄

第1章 序文

第2章 前提與調查手法

第3章 摘要整理:全球IBD(潰瘍性大腸炎、克隆氏症)治療藥市場

第4章 市場概要

  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球IBD(潰瘍性大腸炎、克隆氏症)治療藥的市場價值預測(2017年～2031年)

第5章 主要洞察

  • 開發平台分析
  • 主要的產業活動
  • COVID-19流行對產業的影響(價值鏈，短、中、長期性的影響)

第6章 全球IBD(潰瘍性大腸炎、克隆氏症)治療藥市場分析與預測:醫藥品分類

  • 簡介和定義
  • 主要調查結果/開發
  • 市場價值預測:醫藥品分類(2017年～2031年)
    • TNF抑制劑
    • 胺基水楊酸
    • 整合素拮抗劑
    • 皮質類固醇
    • 其他
  • 市場魅力分析:各醫藥品分類

第7章 全球IBD(潰瘍性大腸炎、克隆氏症)治療藥市場分析與預測:各適應症

  • 簡介和定義
  • 主要調查結果/開發
  • 市場價值預測:各適應症(2017年～2031年)
    • 潰瘍性大腸炎
    • 克隆氏症
  • 市場魅力分析:各適應症

第8章 全球IBD(潰瘍性大腸炎、克隆氏症)治療藥市場分析與預測:各流通管道

  • 簡介和定義
  • 主要調查結果/開發
  • 市場價值預測:各流通管道(2017年～2031年)
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場魅力分析:各流通管道

第9章 全球IBD(潰瘍性大腸炎、克隆氏症)治療藥市場分析與預測:各地區

  • 主要調查結果
  • 市場價值預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 市場魅力分析:各地區

第10章 北美的IBD(潰瘍性大腸炎、克隆氏症)治療藥市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:各醫藥品分類(2017年～2031年)
    • TNF抑制劑
    • 胺基水楊酸
    • 整合素拮抗劑
    • 皮質類固醇
    • 其他
  • 市場價值預測:各適應症(2017年～2031年)
    • 潰瘍性大腸炎
    • 克隆氏症
  • 市場價值預測:各流通管道(2017年～2031年)
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場價值預測:各國(2017年～2031年)
    • 美國
    • 加拿大
  • 市場魅力分析
    • 各醫藥品分類
    • 各適應症
    • 各流通管道
    • 各國

第11章 歐洲的IBD(潰瘍性大腸炎、克隆氏症)治療藥市場分析與預測

第12章 亞太地區的IBD(潰瘍性大腸炎、克隆氏症)治療藥市場分析與預測

第13章 南美的IBD(潰瘍性大腸炎、克隆氏症)治療藥市場分析與預測

第14章 中東、非洲的IBD(潰瘍性大腸炎、克隆氏症)治療藥市場分析與預測

第15章 競爭情形

  • 市場參與者 - 競爭矩陣(階層、各企業規模)
  • 市場佔有率分析:各企業(2021年)
  • 企業簡介
    • AbbVie, Inc.
    • Allergan plc
    • Bausch Health Companies, Inc.
    • Biogen, Inc.
    • Bristol-Myers Squibb Company
    • Celltrion Healthcare Co., Ltd.
    • Janssen Biotech, Inc. (Johnson & Johnson)
    • Novartis AG
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • UCB, Inc.
    • 其他的有名企業
Product Code: TMRGL1473

The report provides revenue of the global IBD (Ulcerative Colitis & Crohn's Disease) treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global IBD (Ulcerative Colitis & Crohn's Disease) treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the IBD (Ulcerative Colitis & Crohn's Disease) treatment market.

The report delves into the competitive landscape of the global IBD (Ulcerative Colitis & Crohn's Disease) treatment market. Key players operating in the global IBD (Ulcerative Colitis & Crohn's Disease) treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global IBD (Ulcerative Colitis & Crohn's Disease) treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

4. Market Overview

  • 4.1. Overview
  • 4.2. Market Dynamics
    • 4.2.1. Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunities
  • 4.3. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Industry Events
  • 5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. TNF Inhibitors
    • 6.3.2. Aminosalicylates
    • 6.3.3. Integrin Antagonists
    • 6.3.4. Corticosteroids
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 7.3.1. Ulcerative Colitis
    • 7.3.2. Crohn's Disease
  • 7.4. Market Attractiveness Analysis, by Disease Indication

8. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. TNF Inhibitors
    • 10.2.2. Aminosalicylates
    • 10.2.3. Integrin Antagonists
    • 10.2.4. Corticosteroids
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 10.3.1. Ulcerative Colitis
    • 10.3.2. Crohn's Disease
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Disease Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. TNF Inhibitors
    • 11.2.2. Aminosalicylates
    • 11.2.3. Integrin Antagonists
    • 11.2.4. Corticosteroids
    • 11.2.5. Others
  • 11.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 11.3.1. Ulcerative Colitis
    • 11.3.2. Crohn's Disease
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Disease Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. TNF Inhibitors
    • 12.2.2. Aminosalicylates
    • 12.2.3. Integrin Antagonists
    • 12.2.4. Corticosteroids
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 12.3.1. Ulcerative Colitis
    • 12.3.2. Crohn's Disease
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. India
    • 12.5.3. Japan
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Disease Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. TNF Inhibitors
    • 13.2.2. Aminosalicylates
    • 13.2.3. Integrin Antagonists
    • 13.2.4. Corticosteroids
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 13.3.1. Ulcerative Colitis
    • 13.3.2. Crohn's Disease
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Disease Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. TNF Inhibitors
    • 14.2.2. Aminosalicylates
    • 14.2.3. Integrin Antagonists
    • 14.2.4. Corticosteroids
    • 14.2.5. Others
  • 14.3. Market Value Forecast, by Disease Indication, 2017-2031
    • 14.3.1. Ulcerative Colitis
    • 14.3.2. Crohn's Disease
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Disease Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. AbbVie, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Allergan plc
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Bausch Health Companies, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Biogen, Inc.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Bristol-Myers Squibb Company
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Celltrion Healthcare Co., Ltd.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Janssen Biotech, Inc. (Johnson & Johnson
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Novartis AG
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Pfizer, Inc.
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Takeda Pharmaceutical Company Limited
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. UCB, Inc.
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Other Prominent Players

List of Tables

  • Table 01: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 03: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 08: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 12: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 16: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 19: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 20: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 23: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031
  • Table 24: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Market Value Share, by Drug Class, 2021
  • Figure 03: Market Value Share, by Disease Indication, 2021
  • Figure 04: Market Value Share, by Distribution Channel, 2021
  • Figure 05: Market Value Share, by Region, 2021
  • Figure 06: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 07: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2022-2031
  • Figure 08: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2017-2031
  • Figure 09: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Aminosalicylates, 2017-2031
  • Figure 10: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Integrin Antagonists, 2017-2031
  • Figure 11: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2017-2031
  • Figure 12: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017-2031
  • Figure 13: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031
  • Figure 14: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2022-2031
  • Figure 15: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ulcerative Colitis, 2017-2031
  • Figure 16: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Crohn's Disease, 2017-2031
  • Figure 17: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 18: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2022-2031
  • Figure 19: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2017-2031
  • Figure 20: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2017-2031
  • Figure 21: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2017-2027
  • Figure 22: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Region, 2021 and 2031
  • Figure 23: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Region, 2022-2031
  • Figure 24: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2031
  • Figure 25: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 26: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 27: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 28: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 29: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 30: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 31: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 32: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 33: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2031
  • Figure 34: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 35: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 37: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 38: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 39: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 40: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 41: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 42: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 43: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
  • Figure 44: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Country/Sub-region, 2022-2031
  • Figure 45: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 46: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031
  • Figure 47: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 48: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2022-2031
  • Figure 49: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2022-2031
  • Figure 50: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2022-2031
  • Figure 51: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2031
  • Figure 52: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 53: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
  • Figure 54: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 55: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031
  • Figure 56: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 57: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 58: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031
  • Figure 59: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 60: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 61: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Country/Sub-region, 2021 and 2031
  • Figure 62: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Country/Sub-region, 2022-2031
  • Figure 63: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031
  • Figure 64: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031
  • Figure 65: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031
  • Figure 66: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2022-2031
  • Figure 67: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2022-2031
  • Figure 68: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2022-2031